Front Page News

Cure SMA Launches LifeVac Support Program to Help in Choking Event

April 12, 2021
Posted in ,

Along with funding SMA research and care, Cure SMA is proud to provide thousands of individuals with SMA and their families with vital support they […]

Read More ›

Scholar Rock Community Statement on TOPAZ 12-Month Topline Data

April 6, 2021
Posted in , , ,

Scholar Rock provided the below community statement on data for apitegromab (SRK-015) following the distribution of this company press release.  Dear Members of the SMA […]

Read More ›

Community Spotlight: Nick Farrell

April 2, 2021
Posted in ,

In honor of National Volunteer Month in April, Cure SMA is sharing stories and quotes from volunteers who support our programs and further grow our […]

Read More ›

Cure SMA-Funded Researcher, Chad Heatwole, Publishes Paper on SMA-HI, a Clinical Trial Outcome in Adults with SMA

March 23, 2021
Posted in ,

Dr. Chad Heatwole, a Cure SMA-funded researcher, and his team have published a paper in the Journal, Muscle Nerve, titled “The Spinal Muscular Atrophy Health […]

Read More ›

Nusinersen Research Updates Presented by Biogen

March 19, 2021
Posted in , ,

Biogen recently presented data about ongoing studies of SPINRAZA (nusinersen) in patients with Spinal Muscular Atrophy. Updates included the NURTURE, ENDEAR, SHINE, DEVOTE, and RESPOND […]

Read More ›

Research Updates from Scholar Rock

March 19, 2021
Posted in , ,

Scholar Rock Presents TOPAZ Interim Analysis Data for Apitegromab in SMA Scholar Rock recently shared 6-month interim analysis data from the TOPAZ Phase 2 clinical […]

Read More ›

Community Statement from Genentech

March 18, 2021
Posted in ,

Dear SMA Community, Based on our commitment to the SMA community to provide transparent, timely updates related to our medicines, we are writing to share […]

Read More ›

Community Statement from Novartis Gene Therapies

March 18, 2021
Posted in ,

Dear Cure SMA Community, Novartis Gene Therapies is committed to patient safety and the ongoing monitoring of adverse events as it relates to the use […]

Read More ›

Evrysdi Research Updates from Genentech

March 18, 2021
Posted in , ,

New 2-year data show Evrysdi continues to demonstrate improvement or maintenance of motor function in people aged 2-25 years with Type 2 or 3 SMA […]

Read More ›

Zolgensma Research Updates from Novartis Gene Therapies

March 18, 2021
Posted in , ,

New Zolgensma data demonstrate age-appropriate development when used early, real-world benefit in older children, and durability 5+ years post-treatment Novartis Gene Therapies recently shared new […]

Read More ›
Scroll to Top